Gleamer has completed a €7.5 million financing round led by historical investor XAnge. This transaction was carried out with the participation of MACSF, Majycc and Crista Galli Ventures, as well as historical investors Elaia and the Ambition Amorçage Angels fund (F3A). The company, founded in 2017, had previously raised €1.5 million in 2018.
The startup's first software, BoneView, is a semi-automated diagnostic tool for radiologists focusing on trauma cases. BoneView is part of Gleamer's AI platform, which aims to assist radiologists in their work. The company claims that using the software has led to a 30% reduction in undetected fractures, in addition to saving time.
Gleamer's investors include 37 radiologists, as well as the companies mentioned above. The startup has been conducting research for over two years, and has now gained CE marking for BoneView. The funding will be used to accelerate the international commercialization of BoneView and to expand the range of software products for radiology.
XAnge, a venture capital firm and subsidiary of the La Poste Group, led the funding round. MACSF is a French insurance company that specializes in healthcare professionals, while Crista Galli Ventures is a European VC firm that focuses on healthcare innovation. Majycc is an investment firm focused on healthcare and life sciences, and Elaia is a French VC firm that invests in technology startups. The Ambition Amorçage Angels (F3A) fund is a government-backed initiative that supports early-stage startups in France.
Gleamer's funding round is a testament to the growing importance of AI-powered medical imaging software. The company's innovative approach to radiology has attracted significant interest from investors, and the additional funding will allow them to expand their product offerings and reach a wider audience.
